The GOLD 2023 and 2024 reports recommend that health professionals consider triple therapy (TT) entailing combined use of a long-acting β 2 agonist (LABA), a long-acting muscarinic antagonist (LAMA), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback